Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma - Scorecard - MDSpire

Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

  • By

  • Mahir Hasan

  • Wolfram Samlowski

  • Samer Nakhle

  • May 8, 2026

  • 0 min

Share

Clinical Scorecard: Routine Monitoring Reveals Elevated Rates of Hypopituitarism After Ipilimumab and Nivolumab Combination Therapy in Metastatic Melanoma Patients

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with metastatic melanoma receiving first-line combination immunotherapy.
Care Setting

Key Highlights

  • Clarify correlation with clinical outcomes.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Regular monitoring of pituitary and thyroid function every 3-4 weeks during treatment.

      Risks

        Patient & Prescribing Data

        Endocrinopathy often presents during active treatment, with delayed onset being uncommon; specify timing relative to treatment cycles.

        Clinical Best Practices

        • Include follow-up recommendations post-treatment.

        References

        Original Source(s)

        Systematic monitoring identified a high incidence of hypopituitarism following combined ipilimumab plus nivolumab therapy for metastatic melanoma

        • by Mahir Hasan, Wolfram Samlowski, Samer Nakhle

        • May 8, 2026

        Related Content

        Case Report: Atypical pattern of pathologic response in cutaneous transdifferentiated melanoma with rhabdomyoblastic differentiation following neoadjuvant therapy

        Error in Tables 2 and 3

        • May 1, 2026

        Melan-Dx: a knowledge-enhanced vision-language framework improves differential diagnosis of melanocytic neoplasm pathology